Danaher (DHR) Stock Price, News & Analysis

Company Overview

Danaher Corporation is a global science and technology innovator headquartered in Washington, D.C., that designs, manufactures and markets products and services to professional, medical, industrial and commercial customers. The company operates through three core segments: Life Sciences, Diagnostics and Environmental & Applied Solutions. Its Life Sciences segment provides critical tools and instruments for research, bioprocessing, drug discovery and genomic analysis, featuring well-known brands such as Cytiva, Beckman Coulter Life Sciences and Leica Microsystems.

The Diagnostics segment offers a portfolio of systems and consumables for clinical diagnostics, molecular diagnostics, pathology and genetics testing. This includes products from Cepheid, Beckman Coulter Diagnostics and Radiometer. Meanwhile, the Environmental & Applied Solutions segment delivers instrumentation, consumables and software for water quality analysis, chemical processing, product identification and product inspection, with leading brands such as Hach, Pall Corporation and Videojet Technologies.

Originally founded in 1969 as Diversified Tool & Die, the company adopted the Danaher name following a strategic realignment in the early 1980s. Over more than five decades, Danaher has pursued a disciplined acquisition strategy to expand its capabilities, integrating over 200 businesses into its platform. Today, the company serves customers in more than 60 countries, leveraging a global network of research and manufacturing facilities to address complex challenges in health care, environmental sustainability and industrial productivity.

Danaher is led by an executive management team overseen by Chief Executive Officer Rainer Blair and a Board of Directors that emphasizes continuous improvement through its proprietary Danaher Business System. With a focus on innovation and operational excellence, the company aims to advance science and technology while delivering solutions that enhance quality of life worldwide.

Key Stats

• Today's Range: $199.35 to $202.39
• 50-Day Range: $184.79 to $204.85
• 52-Week Range: $171.00 to $281.70
• Volume: 584,597 shs
• Average Volume: 3.50 million shs
• Market Capitalization: $142.74 billion
• P/E Ratio: 38.76
• Dividend Yield: 0.64%
• Price Target: $248.61
• Consensus Rating: Moderate Buy

Danaher Stock Analysis - MarketRank™

Danaher scored higher than 97% of companies evaluated by MarketBeat, and ranked 51st out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Danaher has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 16 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Danaher has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 12.32%

Earnings Growth

Earnings for Danaher are expected to grow by 12.32% in the coming year, from $7.63 to $8.57 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Danaher is 38.75, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.07.

Price to Earnings Ratio vs. Sector

The P/E ratio of Danaher is 38.75, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.23.

Price to Earnings Growth Ratio

Danaher has a PEG Ratio of 2.77. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Danaher has a P/B Ratio of 2.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.19% of the float of Danaher has been sold short.

Short Interest Ratio / Days to Cover

Danaher has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Danaher has recently increased by 4.17%, indicating that investor sentiment is decreasing.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Danaher has a dividend yield of 0.65%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Danaher has only been increasing its dividend for 2 years.

Dividend Coverage

The dividend payout ratio of Danaher is 24.85%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Danaher will have a dividend payout ratio of 14.94% next year. This indicates that Danaher will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.47

Percentage of Shares Shorted

1.19% of the float of Danaher has been sold short.

Short Interest Ratio / Days to Cover

Danaher has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Danaher has recently increased by 4.17%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.25

News Sentiment

Danaher has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 52 news articles for Danaher this week, compared to 29 articles on an average week.

Search Interest

Only 18 people have searched for DHR on MarketBeat in the last 30 days. This is a decrease of -5% compared to the previous 30 days.

MarketBeat Follows

7 people have added Danaher to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Danaher insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $249,054,390.00 in company stock.

Percentage Held by Insiders

11.20% of the stock of Danaher is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

79.05% of the stock of Danaher is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DHR Stock Analysis - Frequently Asked Questions

How have DHR shares performed this year?

Danaher's stock was trading at $229.55 at the beginning of the year. Since then, DHR shares have decreased by 12.9% and is now trading at $199.96.
View the best growth stocks for 2025 here.

How were Danaher's earnings last quarter?

Danaher Corporation (NYSE:DHR) issued its quarterly earnings data on Tuesday, April, 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. The conglomerate had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a net margin of 15.81% and a trailing twelve-month return on equity of 10.80%.
Read the conference call transcript.

Does Danaher have any subsidiaries?

Danaher subsidiaries include these companies: Aldevron, Precision NanoSystems, Aquatic Informatics, Cytiva, GE Biopharma, Integrated DNA Technologies, IDBS Group, and more.

Who are Danaher's major shareholders?

Danaher's top institutional shareholders include Park National Corp OH (0.01%), Neville Rodie & Shaw Inc. (0.01%), Legacy Wealth Management LLC MS and Harbor Investment Advisory LLC. Insiders that own company stock include Steven M Rales, Alan G Spoon, Rainer Blair, Joakim Weidemanis, Linda Filler, Daniel Raskas, Matthew Mcgrew, Brian W Ellis, Teri List, Christopher Paul Riley, Walter G Lohr, Raymond C Stevens, Jennifer Honeycutt, Jose-Carlos Gutierrez-Ramos and Georgeann Couchara.
View institutional ownership trends.

How do I buy shares of Danaher?

Shares of DHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Danaher own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Danaher investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), UnitedHealth Group (UNH), BlackRock (BLK), JPMorgan Chase & Co. (JPM) and Advanced Micro Devices (AMD).

Company Calendar

• Record date for 4/25 Dividend: 3/28/2025
• Ex-Dividend for 4/25 Dividend: 3/28/2025
• Last Earnings: 4/22/2025
• Dividend Payable: 4/25/2025
• Record date for 7/25 Dividend: 6/27/2025
• Today: 7/02/2025
• Next Earnings (Estimated): 7/22/2025
• Dividend Payable: 7/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Industrial Conglomerates
• Current Symbol: NYSE:DHR
• CIK: 313616
• Web: www.danaher.com
• Phone: (202) 828-0850
• Fax: 202-828-0860
• Employees: 63,000
• Year Founded: 1984

Price Target and Rating

• Average Stock Price Target: $248.61
• High Stock Price Target: $315.00
• Low Stock Price Target: $210.00
• Potential Upside/Downside: +23.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 20 Analysts

Profitability

• EPS (Trailing Twelve Months): $5.15
• Trailing P/E Ratio: 39.03
• Forward P/E Ratio: 26.34
• P/E Growth: 2.77
• Net Income: $3.90 billion
• Net Margins: 15.81%
• Pretax Margin: 18.91%
• Return on Equity: 10.80%
• Return on Assets: 6.89%

Debt

• Debt-to-Equity Ratio: 0.31
• Current Ratio: 1.43
• Quick Ratio: 1.05

Sales & Book Value

• Annual Sales: $23.88 billion
• Price / Sales: 6.03
• Cash Flow: $11.12 per share
• Price / Cash Flow: 18.08
• Book Value: $68.60 per share
• Price / Book: 2.93

Miscellaneous

• Outstanding Shares: 715,670,000
• Free Float: 635,515,000
• Market Cap: $143.85 billion
• Optionable: Optionable
• Beta: 0.77